anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Up to a quarter of all hospitalized patients undergo bladder catheterization, regardless of the department profile. Injuries related to this procedure represent up to 32% of all urethral injuries and may compromise or worsen the patients treatment. The most frequent causes of iatrogenic injury in this context are unintentional balloon inflation in the urethra or the creation of a false passage. The purpose of our work was to identify the most effective methods to prevent these injuries. Articles containing the following information were selected: iatrogenic injuries of the urethra, the effectiveness of injury prevention methods, various devices and drugs. The work also included reviews evaluating the effectiveness of various catheterization techniques and data on the significance of the type and material of the catheter. We reviewed about 20 papers that discussed the frequency of iatrogenic injuries, their early and long-term consequences and ways to prevent them. Urethral strictures are the most common complication of catheterization in the long-term period (78%). The remaining 22% had no consequences. Most researchers agree that the most effective way to prevent injury is the correct catheter insertion technique and the use of additional assets in the form of anesthetic gels-lubricants. In cases of difficult catheterization, modified techniques with different types of catheters can help: catheters with a curved tip or made of more rigid materials. Safety valves that prevent the balloon inflation in the urethra, or visus catheters that help to detect and solve the problem safely, can prevent a traumatic effect. As a result of our work we have found several approaches to reduce the frequency of injuries. The most accessible and easiest way is to follow the catheterization algorithms, the second and important way is to use proper premedication in the form of gels with anesthetics. In cases of complex catheterization, use a Coude or silicone catheter, and in cases that do not allow catheterization without visual control, use visus catheters.
The investigational device is part of a treatment concept for edentulous patients of all ages, gender and races. The incidence for tooth loss has not declined over years, and the prevalence for edentulism is significantly higher for adults 50 years and older. For this descriptive two-part survey, no minimum number of patients is defined, but to achieve a reasonable subject number, a minimum of five (5) patients will be enrolled, i.e. 10 dentures will be fabricated within this study.
The proposed study is a prospective evaluation of data from patients undergoing primary total hip arthroplasty using the Trident II acetabular cup. Fifty patients will be recruited for this study. All patients that qualify for the study per the inclusion-exclusion criteria and provide written informed consent will receive the Trident II acetabular cup and RSA beads. Implant stability, through RSA, will be measured throughout the first two postoperative (post-op) years per the following schedule: immediate post-op and 6 weeks, 3 months, 6 months, 1 year, and 2 years following surgery. Patients will be discharged and seen for follow-up assessments as per standard of care. Adverse events that are related to the index joint will be collected. Health outcome questionnaires will be collected. The health outcome questionnaires will include: EQ-5D, HOOS JR and Harris Hip Score. Health outcome questionnaires will be completed pre-operatively and again at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery. Conventional x-ray analysis will be performed pre-operatively and again at 6 weeks, 1 year and 2 years following surgery.
Tobacco-related illness causes over 5 million deaths per year in the developed world, and most currently available smoking cessation treatments do not effectively enhance long-term cessation outcomes. Reactivity to smoking cues is one factor associated with relapse vulnerability, which is untreated by cessation aids such as NRT. Combining treatments, which ameliorate both pharmacological nicotine withdrawal and reduce smoking cue reactivity, may enhance smoking cessation success. During this study we will test whether combining NRT with non-nicotine containing electronic cigarettes (e-cigarettes) effectively reduces reactivity to smoking cues. The only source of nicotine participants will receive during the study will come from NRT. We will use e-cigarettes that provide no nicotine, yet may provide a similar experience to smoking as e-cigarettes taste and feel similar to a regular cigarette. However, since nicotine delivery is not associated with the act of smoking the reinforcing effects associated with smoking behavior may be reduced. Reactivity to smoking cues will be assessed using a battery of measures including: self-report, behavioral, and neuroimaging.
The subject population will be obtained by approaching the Principal and Co- Investigators' patients who have been referred for ICD implantation or who already have an ICD. This population ranges in age from 18 years on, and includes both males and females. A maximum of 50 subjects will be enrolled in this study.
Genome-Wide Non-Invasive Prenatal Testing (GW-NIPT) can provide positive results not only for common autosomal aneuploidies but also for rare autosomal trisomies (RATs) and structural chromosomal abnormalities (StrCAs). Due to their rarity, there is currently insufficient information on positive predictive value PPV of RAT and StrCA-positive cases in the literature. In this study, the screening accuracy and pregnancy outcomes of cases positive for rare chromosomal abnormalities were examined based on publications in which GW-NIPT testing was performed. True positive cases were determined using two different methodologies. One was a confirmed methodology, where only cases validated by genetic testing were considered true positives with a definite diagnosis, and the other was an extended methodology, where, in addition to cases confirmed by genetic testing, intrauterine fetal death and termination of pregnancy due to an abnormality confirmed by ultrasound examination were also considered true positives, where no diagnosis had been made but the fetus was probably affected. Seventeen studies were analyzed, with a total GW-NIPT population of 740,076. Of these, 1,738 were RAT positive. Using the confirmed method, we found the highest rates of true positives in T16, followed by T22, and T2, using the extended method, the highest rate of true positives in T15, T16 and T22. This is the first meta-analysis to determine the frequency of rare chromosomal abnormalities, test-positive rates, and the PPV of each chromosomal abnormality with high precision. Our results could aid pre- and post-test genetic counselling and help patients and clinicians in their decision-making.
The oral LD50 of ALDACTONE is greater than 1000 mg/kg in mice, rats, and rabbits.

Acute overdosage of ALDACTONE may be manifested by drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Rarely, instances of hyponatremia, hyperkalemia, or hepatic coma may occur in patients with severe liver disease, but these are unlikely due to acute overdosage. Hyperkalemia may occur, especially in patients with impaired renal function.

Treatment: Induce vomiting or evacuate the stomach by lavage. There is no specific antidote. Treatment is supportive to maintain hydration, electrolyte balance, and vital functions. Patients who have renal impairment may develop hyperkalemia. In such cases, discontinue ALDACTONE.
The invention relates to a method for intelligently fusing CT image data with MRI data. S1, CT image data and MRI data are acquired: CT image data and MRI data of a patient are acquired by a medical imaging device. The data are stored in a digital mode and transmitted to a server through a network for subsequent processing. S2, data preprocessing: the acquired CT image data and MRI data are preprocessed, including image denoising and image enhancement operations, so as to improve image quality and reduce noise. S3, feature extraction: feature information including gray scale values, texture features, morphological features is extracted from the CT image data and MRI data. The characteristic information represents different aspects of the image, including density and structure. S4, feature fusion: features extracted from CT image data and MRI data are fused to generate a comprehensive feature vector. The fusion method comprises linear weighting and statistical analysis to obtain accurate and comprehensive characteristic information.
The present invention relates to binding pockets of receptor tyrosine kinases (RTKs). The binding pockets may regulate the kinase domain of the receptor tyrosine kinases. In particular, the invention relates to a crystal comprising a binding pocket of a receptor tyrosine kinase that regulates the kinase domain of the receptor tyrosine kinase EphB2. The crystal may be useful for modeling and/or synthesizing mimetics of a binding pocket or ligands that associate with the binding pocket. Such mimetics or ligands may be capable of acting as modulators of receptor tyrosine kinase receptor activity, and they may be useful for treating, inhibiting, or preventing diseases modulated by such receptors. Methods are also provided for regulating the kinase domain of an RTK by changing a binding pocket of the RTK that regulates the kinase domain from an autoinhibited state to an active state or from an active state to an autoinhibited state.
This study is a pilot, single-arm intervention of Emotion Regulation Therapy for Cancer Caregivers (ERT-C). We plan to recruit a pilot sample 32 consented (24 evaluable) caregivers of patients diagnosed with cancer and measure their distress, anxiety, and other psychological outcomes at baseline. Caregivers will be consented into an 8-session ERT-C therapy (approximately 12 - 16 weeks).
The present invention is a product for restricting the flow of airborne  contaminants into a nasal passage (3). It involves, in its most general terms, means for creating an electrostatic field (5) in an area near a nasal passage. The electrostatic field may either repel or attract airborne contaminants or both. The product may take the form of a plurality of masses of one or more electrostatic materials, the masses have an average cross-sectional area of about one square millimeter to about 50,000 square millimeters, the mass being of sufficient charge to create an electrostatic field (5) which will prevent at least some airborne contaminants from passing into a nasal passage (3).  Also included in these embodiments  would be a carrier material with the plurality of masses dispersed therethrough. The product may be a topical solution, a semi solid, a spray solution or a vaporizable solution.  Alternatively, it may be in a form which includes a substrate for the carrier and, in one preferred embodiment, the substrate would be an adhesive material such as a bandage.  The present invention also includes methods of preventing airborne contaminants from entering nasal passages utilizing the aforesaid products.
NEW MATERIAL:An azacycloalkane derivative shown by formula I (R is alkyl; m is 5-7; n is 3-15). EXAMPLE:1-(3-Octyloxypropyl)azacycloheptan-2-one. USE:Useful as an absorption promotor having improved action on permeability and permeation of drug by blending drug with a specific amount of the promotor. The promotor itself has antimicrobial action. Use of the promotor can maintain durability of drug, further adjusts absorption rate of drug and prevents side effects caused by excess administration. The promotor has merits wherein a drug causing liver disorder can be relatively safely administered. PREPARATION:As shown a reaction formula (M is alkali metallic ion and X is halogen, etc.,), a compound shown by formula III obtained from an azacycloalkane-2-one and an alkali catalyst is reacted with an alcohol in the presence of an alkali catalyst to give a compound shown by formula I.
Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 480μg dose on Day 1.
Gastro-intestinal (GI) cancer is becoming the top-ranked high mortality cancer in recent years. Every year, approximate 5,300,000 people in China are diagnosed with cancer, of which about 2,000,000 die each year, and esophagus cancer, gastric cancer and colorectal cancer account for \~50% of all GI cancer cases. GI cancer causes 500 thousand deaths a year. In China, nearly 85% of patients with cancer of the digestive tract are in middle to late stage at diagnosis. Regardless of the treatment, the five year survival rate is only 36%. GI cancers include cancer in the oral cavity, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum) and large intestine (cecum, colon, rectum). The main malignant tumors of the GI tract are esophageal, gastric, colorectal, liver, and pancreatic cancer.

Adoptive immunotherapy based on cytotoxic T lymphocytes reactive with specific antigens has proven to be effective in many studies. In vitro induction of cancer antigen-specific immune cells and genetic engineering of target specific immune cells have great potential for cancer eradication. This study aims to evaluate the safety and efficacy of ex vivo manipulated EIE cells including chimeric antigen receptor (CAR) modified immune cells in treating cancer. The primary study objectives are to evaluate the safety of the investigational product, autologous EIE cells, to subjects by intravenous and intratumoral injections. The secondary study objectives are (1) to evaluate the success rate of generating autologous EIE cells ex vivo, and (2) to determine the anti-cancer efficacy of the EIE cells.
PCT No. PCT/AU90/00013 Sec. 371 Date Sep. 18, 1991 Sec. 102(e) Date Sep. 18, 1991 PCT Filed Jan. 19, 1990 PCT Pub. No. WO90/07932 PCT Pub. Date Jul. 26, 1990.A method for degrading fibrin deposits and preventing such deposits associated with pathological conditions is described, which comprises administering to a subject in need of such treatment a therapeutically effective amount of IL-4 activity, optionally in association with one or more pharmaceutically acceptable carriers or excipients. There is also described thrombolytic compositions which comprise IL-4 or a derivative thereof possessing IL-4 activity together with a pharmaceutically acceptable carrier or excipient.
Visit 1: Consenting and screening for study criteria. Visit 1 consists of consenting and screening session. Potential subjects will arrive at CNRC at 8h30 after 10-hour overnight fast (at least), only allowed access to water. A copy of written participant information sheet and informed consent form (ICF) will be given for them to read through carefully with needed time, and they may question for unclarity. Upon satisfaction, subjects must sign the ICF prior to the study procedures. After the consent, subjects will be screened for their eligibility with health screening questionnaire, and undergo anthropometric measurements (i.e. weight, height, waist circumference, and hip circumference). BMI will be calculated using formular weight divided by meter square (kg/m2). Blood pressure and heart rate readings will be taken. Body composition will be assessed using bioimpedance (BIA). Female subjects will be required to perform a β-HCG test using a urinary pregnancy test kit. Fasting glucose test will be performed through finger prick.

Visit 2 and 3: Intervention study (durian or banana will be assigned randomly) Visit 2 and visit 3 correspond to test session. Female subjects will be tested in the follicular phase of the menstrual cycle (the last menstrual cycle will be noted during screening and regular follow-up for the update). On each test day, subjects will arrive at CNRC at 8h30 after 10-hour overnight fast (at least), only water is allowed. They will undergo anthropometric measurements, and then instructed to lay comfortably on a bed in a suite (room temperature 22-24°C) for 45-minute of resting metabolic rate (RMR) measurement. Blood pressure, heart rate, fasting blood glucose, and fasting lipid will be performed before the meal test. At 9h30, subjects will be served 250g of durian or 417.6g of banana in a plate with 200 mL of water, and requested to consume the entire test meal within 10 min. Thermic effect of test meal will be performed after ingestion for 3 hours. Blood glucose fluctuation will be measured at 15 min, 30 min, 60 min, 90 min, 120 min, 180 min, and lipid fluctuation will be measured at 60 min, 120 min, and 180 min by finger prick. Blood pressure and heart rate readings will be taken at 30 min, 60 min, 120 min, 180 min.
The invention belongs to the technical field of antitumor drugs, and particularly discloses a preparation method and application of an AIE type photosensitizer mainly used for type I photodynamic therapy. The chemical structure of the AIE photosensitizer is shown as a formula (I): the photosensitizer of the invention can improve the coupling constant due to the heavy atomic effect of sulfur atoms, is favorable for intersystem crossing of excitons, improves the yield of active oxygen generated by the photosensitizer TM, and has good photodynamic therapy effect. The photosensitizer TM skeleton contains R  1  The group-substituted tetraphenyl ethylene unit shows obvious aggregation inductionLight emitting (AIE) performance. AIE photosensitizers are capable of rapidly generating cytotoxic superoxide anion radicals (. O) by electron transfer  2   ‑  ) Killing tumor cells and achieving the purpose of inhibiting tumor growth. The preparation method of the photosensitizer has the advantages of easily available raw materials, mild synthesis conditions, simple preparation method, convenient purification and easy realization, and has great application prospect.
Renal Impairment

The impact of renal impairment on the pharmacokinetics of guanfacine in children was not assessed. In adult patients with impaired renal function, the cumulative urinary excretion of guanfacine and the renal clearance diminished as renal function decreased. In patients on hemodialysis, the dialysis clearance was about 15% of the total clearance. The low dialysis clearance suggests that the hepatic elimination (metabolism) increases as renal function decreases. It may be necessary to adjust the dose in patients with significant impairment of renal function.

Hepatic Impairment

The impact of hepatic impairment on PK of guanfacine in children was not assessed. Guanfacine in adults is cleared both by the liver and the kidney, and approximately 50% of the clearance of guanfacine is hepatic. It may be necessary to adjust the dose in patients with significant impairment of hepatic function.
The invention relates to a traditional Chinese medicine composition for preventing miscarriage of pregnant sows and a preparation method thereof. The composition is prepared from the following traditional Chinese medicine raw materials: Chinese angelica, prepared rehmannia root, Szechuan lovage rhizome, codonopsis pilosula, fried milkvetch root, fried largehead atractylodes rhizome, tangerine peel, argy wormwood leaf, baical skullcap root, indigowoad leaf, isatidis root, licorice root, white peony root, eucommia bark, Chinese dodder seed and honeysuckle flower. Various components in the composition are proportioned according to an appropriate proportion, and match with one another. The traditional Chinese medicine composition has the characteristics that the raw materials are easy to obtain, the preparation is simple, the cost is low, and the composition is economical and practical. The traditional Chinese medicine composition provided by the invention has a main effect of benefiting qi and nourishing blood, and also has the functions of invigorating spleen and kidney, nourishing sources to stabilize Chong-Ren, and eliminating pathogenic toxins. Test data of miscarriage prevention results of the pregnant sows show that the traditional Chinese medicine composition is high in safety, reliable in curative effect, and significant in effect. To sum up, the formula of the traditional Chinese medicine composition, provided by the invention, has the characteristics of being efficient, low in price, and safe in miscarriage prevention of the pregnant sows.
PURPOSE: An HL7 CDA(Clinical Document Architecture) standard based personal health state measurement data management system is provided to extract header information and health state measurement information by analyzing personal health data. CONSTITUTION: A receiver(110) receives a device CDA from a health gateway(200). A CDA analyzer(120) analyzes the received device CDA and extracts the header information and the health measurement information. A user/device DB(131) stores the header information extracted from the CDA analysis section. A PHR DB(132) stores the health measurement information extracted from the CDA analysis section. A health history inquiry request processor(140) searches the user/device DB and the PHR DB by the request of the health history.
According to experimental and clinical studies, status epilepticus (SE) causes neurodegenerative morphological changes not only in the hippocampus and other limbic structures, it also affects the thalamus and the neocortex. In addition, several studies reported atrophy, metabolic changes, and neuronal degeneration in the dorsal striatum. The literature lacks studies investigating potential neuronal damage in the ventral component of the striatopallidal complex (ventral striatum [VS] and ventral pallidum) in SE experimentations. To better understand the development of neuronal damage in the striatopallidal complex associated with SE, the detected neuronal degeneration in the compartments of the VS, namely, the nucleus accumbens (NAc) and the olfactory tubercle (OT), was analyzed. The experiments were performed on Wistar rats at age of 25-day-old pups and 3-month-old adult animals. Lithium-pilocarpine model of SE was used. Lithium chloride (3 mmol/kg, ip) was injected 24 h before administering pilocarpine (40 mg/kg, ip). This presented study demonstrates the variability of post SE neuronal damage in 25-day-old pups in comparison with 3-month-old adult rats. The NAc exhibited small to moderate number of Fluoro-Jade B (FJB)-positive neurons detected 4 and 8 h post SE intervals. The number of degenerated neurons in the shell subdivision of the NAc significantly increased at survival interval of 12 h after the SE. FJB-positive neurons were evidently more prominent occupying the whole anteroposterior and mediolateral extent of the nucleus at longer survival intervals of 24 and 48 h after the SE. This was also the case in the bordering vicinity between the shell and the core compartments but with clusters of degenerating cells. The severity of damage of the shell subdivision of the NAc reached its peak at an interval of 24 h post SE. Isolated FJB-positive neurons were detected in the ventral peripheral part of the core compartment. Degenerated neurons persisted in the shell subdivision of the NAc 1 week after SE. However, the quantity of cell damage had significantly reduced in comparison with the aforementioned shorter intervals. The third layer of the OT exhibited more degenerated neurons than the second layer. The FJB-positive cells in the young animals were higher than in the adult animals. The morphology of those cells was identical in the two age groups except in the OT.